404 Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancerRichard D. Kim, Aung Naing, Ngocdiep T. Le et al.|Regular and Young Investigator Award Abstracts|2021Cited by 6
408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancerAung Naing, Hirva Mamdani, Richard D. Kim et al.|Regular and Young Investigator Award Abstracts|2021Cited by 4
A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.Richard D. Kim, Aung Naing, Hirva Mamdani et al.|Journal of Clinical Oncology|2024Cited by 3
652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumorsAung Naing, Richard D. Kim, Hirva Mamdani et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1